11 standard-of-care settings across 5 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Active surveillance, partial nephrectomy (usually robotic), or thermal ablation depending on growth, comorbidity, and biopsy; renal mass biopsy increasingly used.
NCCN · 1 (preferred: all four regimens)ESMO-MCBS · 4
98
IMDC risk
Metastatic, favourable risk, first line
IO-TKI doublet (PFS benefit; OS benefit unproven in this group) or single-agentTKI (sunitinib, pazopanib) with deferred IO; active surveillance for indolent low-volume disease.
Single-agentTKI (cabozantinib, axitinib, lenvatinib + everolimus, tivozanib); belzutifan after both IO and VEGF-TKI (LITESPARK-005). Do not rechallenge PD-1 (CONTACT-03, TiNivo-2).
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.